SAR-020106
Based on 1 publication(s) in Google Scholar
SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC50 of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.04%
- No. CAS: 1184843-57-9
- Fòrmula: C19H19ClN6O
- Peso molecular:382.85
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-18174
PrexasertibCHK1 Inhibitor -
HY-10032
PF 477736Chk1 Inhibitor -
HY-15532
SCH900776CHK1 Inhibitor -
HY-18958
CCT245737CHK1 Inhibitor -
HY-18175
CCT244747 -
HY-13263
CHIR-124Checkpoint Kinase (Chk) Inhibitor -
HY-14720
RabusertibCHK1 Inhibitor -
HY-112167
GDC-0575Chk1 Inhibitor -
HY-15532B
SCH900776 (S-isomer)CHK1 Serine/Threonine Kinase Inhibitor -
HY-19926
GDC-0425ChK1 Inhibitor -
HY-148962
LY2880070CHK1 Inhibitor -
HY-10992
AZD-7762Chk Inhibitor
Publications Citing Use of MedChemExpress (MCE) SAR-020106
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
Chk1 13.3 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
5 μM
Compound: 6, SAR-020106
|
Inhibition of human ERG overexpressed in HEK cells
Inhibition of human ERG overexpressed in HEK cells
|
[PMID: 23082860] |
| HT-29 | GI50 |
0.47 μM
Compound: (R)-3, SAR-020106
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 22111927] |
| HT-29 | IC50 |
0.055 μM
Compound: (R)-3, SAR-020106
|
Antimitotic activity in etoposide-induced human HT-29 cells assessed as induction of M-phase phosphoprotein 2 expression by ELISA
Antimitotic activity in etoposide-induced human HT-29 cells assessed as induction of M-phase phosphoprotein 2 expression by ELISA
|
[PMID: 22111927] |
| HT-29 | IC50 |
55 nM
Compound: 6, SAR-020106
|
Inhibition of CHK1 in human HT-29 cells assessed as etoposide-induced G2 check point arrest after 21 hrs by ELISA
Inhibition of CHK1 in human HT-29 cells assessed as etoposide-induced G2 check point arrest after 21 hrs by ELISA
|
[PMID: 23082860] |
In Vitro
SAR-020106 (0.1-1 μM; 23 hours) abrogates an Etoposide-induced S and G2 arrest[1].
SAR-020106 is capable of abrogating Etoposide-induced cell cycle arrest with an IC50 of 55 nM and 91 nM in HT29 and SW620 cells, respectively. SAR-020106 is relatively nontoxic with a GI50 of 0.48 μM in HT29 and 2 μM in SW620, resulting in an activity index of 8.7 and 22, respectively. SAR-020106 inhibits cytotoxic drug-induced autophosphorylation of CHK1 at S296 and blocks the phosphorylation of CDK1 at Y15 in a dose-dependent fashion[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice bearing SW620 xenograft tumors[1]
-
Dosage:40 mg/kg
-
Administration:I.p.; administered on days 0, 1, 7, 8, 14, and 15
-
Result:There was a clear decrease in tumor growth associated with the combination with tumors reaching 300% by 12.5 days.
Chemical Information
-
No. CAS 1184843-57-9
-
Appearance Solid
-
Peso molecular 382.85
-
Fòrmula C19H19ClN6O
-
Color Off-white to light yellow
-
SMILES
N#CC1=NC=C(NC2=CC3=C(C=N2)C(Cl)=CC=C3)N=C1O[C@H](C)CN(C)C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvente y solubilidad
In Vitro:
DMSO : 5 mg/mL (13.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocolo
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Walton MI, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther. 2010;9(1):89-100. [Content Brief]
[2]. Reader JC, et al. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. J Med Chem. 2011;54(24):8328-8342. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6120 mL | 13.0599 mL | 26.1199 mL | 65.2997 mL |
| 5 mM | 0.5224 mL | 2.6120 mL | 5.2240 mL | 13.0599 mL | |
| 10 mM | 0.2612 mL | 1.3060 mL | 2.6120 mL | 6.5300 mL |
SAR-020106 Related Classifications
HY-100195 Related Classifications
Powered by Bioz